BR100 Decreased By (-0.97%)
BR30 Decreased By (-1.02%)
KSE100 Decreased By (-0.76%)
KSE30 Decreased By (-0.82%)
AGHA 7.69 Decreased By ▼ -0.12 (-1.54%)
BECO 5.15 Decreased By ▼ -0.06 (-1.15%)
BML 57.21 Decreased By ▼ -0.29 (-0.5%)
BOP 33.90 Decreased By ▼ -0.13 (-0.38%)
CNERGY 9.94 Decreased By ▼ -0.02 (-0.2%)
CSIL 5.26 Decreased By ▼ -0.05 (-0.94%)
FCCL 53.02 Decreased By ▼ -1.68 (-3.07%)
FFL 16.60 Decreased By ▼ -0.09 (-0.54%)
FNEL 1.22 Decreased By ▼ -0.01 (-0.81%)
KEL 7.22 Decreased By ▼ -0.18 (-2.43%)
KOSM 5.75 Decreased By ▼ -0.02 (-0.35%)
LOTCHEM 29.07 Decreased By ▼ -0.25 (-0.85%)
MLCF 92.20 Decreased By ▼ -2.16 (-2.29%)
NBP 202.80 Decreased By ▼ -0.25 (-0.12%)
NCPL 56.60 Decreased By ▼ -0.40 (-0.7%)
NPL 66.95 Decreased By ▼ -0.75 (-1.11%)
OGDC 314.49 Decreased By ▼ -1.35 (-0.43%)
PACE 10.50 Decreased By ▼ -0.14 (-1.32%)
PAEL 42.08 Decreased By ▼ -1.12 (-2.59%)
PIBTL 16.50 Decreased By ▼ -0.24 (-1.43%)
PPL 216.12 Decreased By ▼ -3.66 (-1.67%)
PRL 50.53 Increased By ▲ 1.34 (2.72%)
PTC 69.98 Decreased By ▼ -0.55 (-0.78%)
SSGC 26.79 Decreased By ▼ -1.46 (-5.17%)
TBL 9.75 Decreased By ▼ -0.11 (-1.12%)
TELE 8.68 Decreased By ▼ -0.11 (-1.25%)
TPL 18.25 Increased By ▲ 0.01 (0.05%)
TPLP 13.57 Increased By ▲ 0.30 (2.26%)
TREET 22.50 Decreased By ▼ -0.22 (-0.97%)
TRG 59.50 Decreased By ▼ -0.64 (-1.06%)
Business & Finance

Pfizer to pursue bringing COVID-19 vaccine to India after import relaxation

  • "We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.
  • "We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."
Published Updated
By

NEW DELHI: Pfizer Inc said on Tuesday it would work towards bringing the COVID-19 vaccine it developed with Germany's BioNTech to India after the government eased import rules, after withdrawing its application in February.

"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.

"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."

Comments

Comments are closed for this article.